| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 80, 356-363, Copyright © 1995 by Endocrine Society
ARTICLES |
SA Beshyah, A Henderson, R Niththyananthan, E Skinner, V Anyaoku, W Richmond, P Sharp and DG Johnston
Unit of Metabolic Medicine, St. Mary's Hospital Medical School, Paddington, London, United Kingdom.
The effects of replacement with biosynthetic human GH on carbohydrate tolerance and lipid metabolism were studied in 40 hypopituitary adults during a randomized double blind, placebo-controlled trial for 6 months, followed by a 12-month open trial. The daily GH dose was 0.04 +/- 0.01 IU/kg. Fasting plasma glucose, serum fructosamine, plasmid lipids, lipoproteins, and plasma C-peptide concentrations were measured, and an oral glucose tolerance test was performed every 6 months. There was no change in fasting triglyceride levels at any stage of the study. There was no significant change in fasting total or LDL cholesterol, total HDL cholesterol, high density lipoprotein2 (HDL2) cholesterol, HDL3 cholesterol, apoprotein-A1, or apoprotein-B during GH or placebo treatment in the placebo-controlled 6-months study. In the open phase of the trial, total and low density lipoprotein cholesterol showed a sustained downward trend during GH therapy. Compared to the pretreatment level, the HDL cholesterol concentration was significantly higher at 18 months. Cholesterol subfractions HDL2 and HDL3 and apoprotein-A1 and -B were not different from the pretreatment levels. The total/HDL cholesterol ratio decreased significantly at 12 and 18 months. During the controlled phase, fasting plasma glucose was similar during GH and placebo administration, but fasting insulin and C-peptide increased during GH therapy, but not during placebo treatment. The mean area under the curve (AUC) for glucose increased by a small, but significant, extent over the 6 months of GH treatment and was higher at 6 months than during placebo treatment. The AUC for insulin also increased during GH treatment. During the open trial, the fasting plasma glucose level increased at 6 and 12 months, and the fasting plasma insulin level increased at 6, 12, and 18 months of GH treatment. The plasma glucose AUC during the oral glucose tolerance test was significantly higher at 6 months, and the plasma insulin AUC was significantly higher at 6, 12, and 18 months of GH therapy. In conclusion, GH therapy has some metabolic effects that are considered beneficial and others that are less desirable.
This article has been cited by other articles:
 |
|
 |
|
  K. Stochholm, T. Laursen, A. Green, P. Laurberg, M. Andersen, L. O. Kristensen, U. Feldt-Rasmussen, J. S. Christiansen, M. Frydenberg, and C. H. Gravholt Morbidity and GH deficiency: a nationwide study. Eur. J. Endocrinol., April 1, 2008; 158(4): 447 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E M Delemarre, J Rotteveel, and H A D.-v. de Waal Metabolic implications of GH treatment in small for gestational age Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S47 - S50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rizzo, R. Trepp, K. Berneis, and E. R Christ Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy Eur. J. Endocrinol., March 1, 2007; 156(3): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R Christ, M. H Cummings, M. Stolinski, N. Jackson, P. J Lumb, A. S Wierzbicki, P. H Sonksen, D. L Russell-Jones, and A M. Umpleby Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study. Eur. J. Endocrinol., March 1, 2006; 154(3): 459 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Maison, S. Griffin, M. Nicoue-Beglah, N. Haddad, B. Balkau, and P. Chanson Impact of Growth Hormone (GH) Treatment on Cardiovascular Risk Factors in GH-Deficient Adults: A Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2192 - 2199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Christ, M. H. Cummings, N. Jackson, M. Stolinski, P. J. Lumb, A. S. Wierzbicki, P. H. Sonksen, D. L. Russell-Jones, and A. M. Umpleby Effects of Growth Hormone (GH) Replacement Therapy on Low-Density Lipoprotein Apolipoprotein B100 Kinetics in Adult Patients with GH Deficiency: A Stable Isotope Study J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1801 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tauber, B. Jouret, A. Cartault, N. Lounis, M. Gayrard, C. Marcouyeux, C. Pienkowski, I. Oliver, P. Moulin, P. Otal, et al. Adolescents with Partial Growth Hormone (GH) Deficiency Develop Alterations of Body Composition after GH Discontinuation and Require Follow-Up J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5101 - 5106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Isley Growth Hormone Therapy for Adults: Not Ready for Prime Time? Ann Intern Med, August 6, 2002; 137(3): 190 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Cook Shouldn't Adults with Growth Hormone Deficiency Be Offered Growth Hormone Replacement Therapy? Ann Intern Med, August 6, 2002; 137(3): 197 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. McConnell, A. B. Atkinson, C. Ennis, D. R. Hadden, D. R. McCance, B. Sheridan, and P. M. Bell The Effects on Insulin Action in Adult Hypopituitarism of Recombinant Human GH Therapy Individually Titrated for Six Months J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5342 - 5347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kearney, C. Navas de Gallegos, A. Chrisoulidou, R. Gray, P. Bannister, S. Venkatesan, and D. G. Johnston Hypopituitarsim Is Associated with Triglyceride Enrichment of Very Low-Density Lipoprotein J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3900 - 3906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Barkan The "Quality of Life-Assessment of Growth Hormone Deficiency in Adults" Questionnaire: Can It Be Used to Assess Quality of Life in Hypopituitarism? J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1905 - 1907. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. J. Hauck and A. Bartke Free Radical Defenses in the Liver and Kidney of Human Growth Hormone Transgenic Mice: Possible Mechanisms of Early Mortality J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2001; 56(4): 153B - 162. [Abstract] [Full Text]
|
|
|
|
|
|
G. Sesmilo, B. M.K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibanski Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial Ann Intern Med, July 18, 2000; 133(2): 111 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. M. Beentjes, A. van Tol, W. J. Sluiter, and R. P. F. Dullaart Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults J. Lipid Res., June 1, 2000; 41(6): 925 - 932. [Abstract] [Full Text]
|
|
|
|
|
|
N. Vahl, A. Juul, J. O. L. Jørgensen, H. Ørskov, N. E. Skakkebæk, and Jens. S. Christiansen Continuation of Growth Hormone (GH) Replacement in GH-Deficient Patients during Transition from Childhood to Adulthood: A Two-Year Placebo-Controlled Study J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1874 - 1881. [Abstract] [Full Text]
|
|
|
|
|
|
B. Bülow, L. Hagmar, J. Eskilsson, and E. M. Erfurth Hypopituitary Females Have a High Incidence of Cardiovascular Morbidity and an Increased Prevalence of Cardiovascular Risk Factors J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 574 - 584. [Abstract] [Full Text]
|
|
|
|
|
|
D. Blank, M. Riedl, A. Reitner, C. Schnack, G. Schernthaner, M. Clodi, H. Frisch, and A. Luger Growth Hormone Replacement Therapy Is Not Associated with Retinal Changes J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 634 - 636. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. L. Vance and N. Mauras Growth Hormone Therapy in Adults and Children N. Engl. J. Med., October 14, 1999; 341(16): 1206 - 1216. [Full Text] [PDF]
|
|
|
|
|
|
J. Gibney, J. D. Wallace, T. Spinks, L. Schnorr, A. Ranicar, R. C. Cuneo, S. Lockhart, K. G. Burnand, F. Salomon, P. H. Sonksen, et al. The Effects of 10 Years of Recombinant Human Growth Hormone (GH) in Adult GH-Deficient Patients J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2596 - 2602. [Abstract] [Full Text]
|
|
|
|
|
|
J. Svensson, J.-O. Jansson, M. Ottosson, G. Johannsson, M.-R. Taskinen, O. Wiklund, and B.-A. Bengtsson Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a) J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2028 - 2033. [Abstract] [Full Text]
|
|
|
|
|
|
M. Pfeifer, R. Verhovec, B. Zizek, J. Prezelj, P. Poredos, and R. N. Clayton Growth Hormone (GH) Treatment Reverses Early Atherosclerotic Changes in GH-Deficient Adults J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 453 - 457. [Abstract] [Full Text]
|
|
|
|
|
|
M. Christopher, F. L. Hew, M. Oakley, C. Rantzau, and F. Alford Defects of Insulin Action and Skeletal Muscle Glucose Metabolism in Growth Hormone-Deficient Adults Persist after 24 Months of Recombinant Human Growth Hormone Therapy J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1668 - 1681. [Abstract] [Full Text]
|
|
|
|
 |
|
 S.-C. J. Yeung, A. C. Chiu, R. Vassilopoulou-Sellin, and R. F. Gagel The Endocrine Effects of Nonhormonal Antineoplastic Therapy Endocr. Rev., April 1, 1998; 19(2): 144 - 172. [Abstract] [Full Text]
|
|
|
|
|
|
P. Lucidi, M. Lauteri, S. Laureti, R. Celleno, S. Santoni, E. Volpi, G. Angeletti, F. Santeusanio, and P. De Feo A Dose-Response Study of Growth Hormone (GH) Replacement on Whole Body Protein and Lipid Kinetics in GH-Deficient Adults J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 353 - 357. [Abstract] [Full Text]
|
|
|
|
|
|
P. V. Carroll, E. R. Christ the members of Growth Hormone Research Soci, B. A. Bengtsson, L. Carlsson, J. S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, et al. Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 382 - 395. [Abstract] [Full Text]
|
|
|
|
|
|
G. P. Ceda, E. Dall’Aglio, A. Magnacavallo, N. Vargas, V. Fontana, M. Maggio, G. Valenti, P. D. K. Lee, R. L. Hintz, and A. R. Hoffman The Insulin-Like Growth Factor Axis and Plasma Lipid Levels in the Elderly J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 499 - 502. [Abstract] [Full Text]
|
|
|
|
|
|
C.-M. Hwu, C. F. Kwok, T.-Y. Lai, K.-C. Shih, T.-S. Lee, L.-C. Hsiao, S.-H. Lee, V. S. Fang, and L.-T. Ho Growth Hormone (GH) Replacement Reduces Total Body Fat and Normalizes Insulin Sensitivity in GH-Deficient Adults: A Report of One-Year Clinical Experience J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3285 - 3292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Burman, A. G. Johansson, A. Siegbahn, B. Vessby, and F. A. Karlsson Growth Hormone (GH)-Deficient Men Are More Responsive to GH Replacement Therapy Than Women J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 550 - 555. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
